KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.LeukemiaPMID 40913104PMC125891202025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.Nat Med已检查 7 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other;Fig. 3:森林图/亚组分析图;Fig. 4:AI 判定为 other;Extended Data Fig. 1:AI 判定为 multi panel km;另有 2 张未列出。PMID 40913168PMC126182382025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.Lancet RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40915298无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.Nat Med已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:CONSORT/入组流程图;Extended Data Fig. 1:AI 判定为 other;Extended Data Fig. 2:AI 判定为 other。PMID 40921806PMC126182482025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.Cancer Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:瀑布图;FIGURE 4:非 KM 图;FIGURE 5:非 KM 图。PMID 40922529PMC125808692025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.Diabetes Obes Metab已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other。PMID 40926359PMC125157632025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Temporal Profile of Treatment-Emergent Adverse Events in Adult Asian Patients with Focal-Onset Seizures During Adjunctive Brivaracetam Treatment: Post Hoc Analysis of a Phase 3, Randomized Trial.Adv Ther已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。PMID 40944847PMC125796732025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.Clin TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40947318无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of DaxibotulinumtoxinA for injection in adults with cervical dystonia: Pooled global analysis of ASPEN-1 and ASPEN-1-CN randomized trials.Parkinsonism Relat DisordPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40961718无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40961952无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40961953无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.Cancer SciPMID 40976711PMC125808632025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Fixed-Dose Brexpiprazole and Sertraline Combination Therapy for the Treatment of Posttraumatic Stress Disorder: A Phase 3, Randomized Trial.J Clin Psychopharmacol已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other。PMID 40982703PMC125736752025 Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed.Adv Ther已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。PMID 40986186PMC125796632025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults.Am J Clin Dermatol已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other。PMID 40993471PMC126155412025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.Arterioscler Thromb Vasc Biol已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:ROC 图;Figure 2:森林图/亚组分析图;Figure 3:研究设计图。PMID 40995631PMC125430012025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial.Drugs已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 multi panel km;Fig. 3:AI 判定为 forest plot;Fig. 4:AI 判定为 multi panel km;Fig. 5:AI 判定为 forest plot;另有 1 张未列出。PMID 41015981PMC125720852025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41033333无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).Gynecol Oncol已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:CONSORT/入组流程图;Fig. 2.:CONSORT/入组流程图;Fig. 3.:CONSORT/入组流程图;Fig. 4.:AI 判定为 multi panel km。PMID 41056581PMC127674592025-Nov0.95The study meets the criteria for being an original, randomized, Phase III trial of a drug-containing intervention (chemoradiation vs. radiation) in human oncology. However, it is excluded because the primary and only reported efficacy endpoints are patient-reported quality of life and symptom outcomes, which do not constitute a time-to-event efficacy endpoint as defined by the cohort criteria.无 KM 图
Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial.Clin Drug Investig入排复审未纳入:The study is a Phase II randomized trial with drug intervention in oncology, but it is not a definitive Phase III trial, and the primary endpoints are hematologic toxicity measures (neutropenia duration, incidence, ANC nadir/recovery) rather than time-to-event efficacy endpoints like OS or PFS.PMID 41066031PMC125355202025-Nov0.85The study is a Phase II randomized trial with drug intervention in oncology, but it is not a definitive Phase III trial, and the primary endpoints are hematologic toxicity measures (neutropenia duration, incidence, ANC nadir/recovery) rather than time-to-event efficacy endpoints like OS or PFS.无 KM 图
Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial.Lancet NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41109232无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study.Lancet Neurol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41109234PMC125502552025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Subgroup Analyses of Post-Marketing Surveillance Data by Age, Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy.Cancer Med入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。PMID 41164972PMC125729502025-Nov0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.ESMO OpenPMID 41167084PMC126070002025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41167216无 PMCID2025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41167217无 PMCID2025-Nov0.95The record describes a randomized, phase 3 trial with time-to-event efficacy endpoints (OS, DFS) and presents original interim results. However, the intervention is a diagnostic/imaging strategy (CT/PET-CT) added to standard physical examination, not a drug-containing intervention. Therefore, it does not meet the inclusion criterion for a drug-containing intervention.无 KM 图
Evaluation of pharmacokinetic interactions between long-acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084.J Int AIDS Soc入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41169120PMC125760192025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Safety outcomes among infants whose mothers used the dapivirine vaginal ring or oral PrEP during pregnancy (MTN-042/DELIVER): a randomised phase 3b study.Lancet HIVPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41173578无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo-Controlled, Double-Blind Treatment Trial.Clin TransplantPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41182019无 PMCID2025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.Target OncolPMID 41184595PMC126692862025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.Mult Scler入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41190505PMC125896702025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.Lancet HaematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41193116无 PMCID2025-Nov0.45The trial is eligible for most criteria (oncology, human, randomized, phase 3, drug intervention, original result), but the required primary/key secondary time-to-event efficacy endpoint is not present. The primary endpoint is a response rate, which is a categorical outcome, not time-to-event. The record's deterministic review correctly identified the lack of a time-to-event signal.无 KM 图
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.Lancet HaematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41193117无 PMCID2025-Nov0.95This is an original result report from a phase 3 randomized trial of drug-containing interventions in oncology. However, the presented results focus exclusively on patient-reported outcomes (secondary/exploratory endpoints), not the primary or key secondary time-to-event efficacy endpoints (e.g., PFS) which are mentioned in the background but not reported here. The report type is secondary (patient-reported outcomes), not the primary efficacy analysis.无 KM 图
Efficacy and Safety of Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis in a China Cohort of a Double-Blind, Randomised, Phase 3 Trial (ReSTORE China).Mycoses已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram。PMID 41194465PMC125899302025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial.Eur J NeurolPMID 41194516PMC125898052025-Nov0.98未发现恶性肿瘤人群证据。已完成
Dupilumab efficacy by disease severity in pediatric type 2 asthma.Pediatr Allergy Immunol已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:CONSORT/入组流程图。PMID 41200848PMC125931812025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Exposure-Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema.Clin Transl Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:AI 判定为 multi panel km;FIGURE 5:非 KM 图;另有 1 张未列出。PMID 41208217PMC125979642025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease.Mol Genet Genomic Med入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41246852PMC126209902025-Nov0.98未发现恶性肿瘤人群证据。无 KM 图
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.ESMO OpenPMID 41320342PMC126847622025-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.J Immunother CancerPMID 41173494PMC125810732025-Oct-310.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.BloodPMID 40737596PMC128246762025-Oct-300.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40923797无 PMCID2025-Oct-300.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.Eur J Endocrinol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41052284无 PMCID2025-Oct-300.98未发现恶性肿瘤人群证据。无 KM 图
One-stage versus two-stage surgery for initially unresectable colorectal cancer liver metastases: post hoc analysis of the CAIRO5 trial.BJS Open入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。PMID 41189486PMC125868482025-Oct-300.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.Eur J Med Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41163129PMC125738512025-Oct-290.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8).BMJPMID 41224473PMC125702752025-Oct-290.98未发现恶性肿瘤人群证据。已完成
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.Blood AdvPMID 40706052PMC125501532025-Oct-280.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial.JAMA已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:森林图/亚组分析图。PMID 41026481PMC124861372025-Oct-280.98未发现恶性肿瘤人群证据。无 KM 图
Implementation of the Study Participant Feedback Questionnaire to understand participant experience in a phase 3 oncology clinical trial.BMJ Open已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。PMID 41151963PMC125709342025-Oct-280.80The record describes a secondary analysis of participant experience in a Phase III randomized oncology trial. While the trial itself is oncology, human, randomized, and Phase III, the specific publication is focused on implementing a feedback questionnaire (quality-of-life/psychosocial measure) and does not report on a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or drug intervention details for this analysis. The deterministic review correctly flagged the absence of a time-to-event signal.无 KM 图
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.LancetPMID 41052510PMC125494782025-Oct-250.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成